New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:39 EDTFOLDAmicus Therapeutics announces 3-in-3 strategy for the next generation ERTs
Amicus Therapeutics provided its FY14 strategic outlook and financial guidance. Key Highlights include: Amicus announces "3-in-3" strategy for three next-generation Enzyme Replacement Therapies, or ERTs, expected to enter the clinic in next three years with lead programs in Fabry, Pompe and Mucopolysaccharidosis I; preclinical proof-of-concept data for next-generation ERTs for Fabry and Pompe to be featured at Lysosomal Disease Network WORLD Symposium and American College of Medical Genetics meetings in 1H14; data from global registration studies of migalastat HCl monotherapy for Fabry disease expected to include complete 12- and 24-month data from Study 011 in 2Q14 and 18-month clinical data from Study 012 in 2H14. Company also stated "As we enter 2014, Amicus is strongly positioned to continue our focus on advancing a pipeline of next-generation enzyme replacement therapies for patients with lysosomal storage diseases. "
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use